Search

Search Results

• 

  Ustekinumab in the treatment of acute disseminated pyoderma gangrenosum in a patient with Crohn’s disease

  Klaudia Miklusiak, Karol Miklusiak, Olga Kaczmarczyk, Dorota Cibor, Małgorzata Zwolińska-Wcisło

  22-05-2023

  https://doi.org/10.4081/dr.2023.9630

  1063

  PDF: 564

  HTML: 75
• 

  Late reaction to ustekinumab infusion

  Marina Resener Morais, Luana Pizarro Meneghello, Carina Flores de Oliveira, André Vicente Esteves Carvalho

  e2

  09-09-2013

  https://doi.org/10.4081/dr.2013.e2

  3965

  PDF: 669

  HTML: 263
• 

  Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces

  Martina Vispi, Teresa Corradin, Camilla Peccianti, Luca Feci, Laura Casini, Chiara Pisani, Susanna Fabbroni, Paola Corsetti, Margherita Croatto, Michele Pellegrino

  25-06-2020

  https://doi.org/10.4081/dr.2020.8642

  1357

  PDF: 752

  HTML: 8
• 

  Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis

  Luca Mastorino, Niccolò Siliquini, Gianluca Avallone, Michela Ortoncelli, Pietro Quaglino, Paolo Dapavo, Simone Ribero

  17-03-2022

  https://doi.org/10.4081/dr.2022.9282

  1168

  PDF: 826

  HTML: 41

• Dermatological insight as the key to diagnosing intestinal Behçet’s disease misdiagnosed as Crohn’s: a case report

  Caterina Mariarosaria Giorgio, Eugenia Veronica Di Brizzi, Gaetano Licata, Carmine Fiorentino, Giuseppe Argenziano, Luca Damiani

  04-02-2025

  https://doi.org/10.4081/dr.2025.10232

  514

  PDF: 307

  HTML: 9
• 

  Atopic dermatitis: a brief review of recent advances in its management

  Sultan Daghafak Alenazi

  23-05-2023

  https://doi.org/10.4081/dr.2023.9678

  2401

  PDF: 1409

  HTML: 106
• 

  Erythrodermic psoriasis treated with apremilast

  John Arcilla, Daniel Joe, Johnathan Kim, Yohanan Kim, VuAnh N. Truong, Navin Jaipaul

  19-09-2016

  https://doi.org/10.4081/dr.2016.6599

  2125

  PDF: 964

  HTML: 601

• Tildrakizumab in the treatment of plaque psoriasis in an HIV+ patient: a case report and literature review of anti-interleukin drugs

  Viviana Lora, Dario Graceffa, Monia Di Prete, Carlo Cota

  11-11-2024

  https://doi.org/10.4081/dr.2024.10140

  995

  PDF: 524

  SUPPLEMENTARY MATERIAL: 155

  HTML: 16
• 

  Exacerbation of generalized plaque psoriasis after tuberculin test

  Alberto Corrà, Lavinia Quintarelli, Alice Verdelli, Walter Volpi, Marzia Caproni

  28-07-2021

  https://doi.org/10.4081/dr.2021.9019

  3189

  PDF: 503

  HTML: 229
• 

  Certolizumab to treat hidradenitis suppurativa

  Asem Shadid, Saud Alobaida, Yousef Binamer

  27-10-2022

  https://doi.org/10.4081/dr.2022.9566

  1940

  PDF: 729

  HTML: 29
• 

  Maculopapular sarcoidosis: the importance of skin signs

  Giovanna Galdo, Gelsomina Luongo, Daniela Capacchione, Damiano Abeni, Marta Grimaldi, Luca Fania

  16-09-2022

  https://doi.org/10.4081/dr.2022.9561

  1011

  PDF: 379

  HTML: 25
• 

  Anti-interleukin-17 and anti-interleukin-23 biologic drugs for genital psoriasis: a single-center retrospective comparative study

  Andrea Cortese, Luigi Gargiulo, Luciano Ibba, Giovanni Fiorillo, Francesco Toso, Carlo Alberto Vignoli, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  19-05-2023

  https://doi.org/10.4081/dr.2023.9692

  1063

  PDF: 546

  HTML: 19
• 

  Dimethyl fumarate as a safe and effective therapy for recalcitrant psoriasis in comorbid patients

  Martina Burlando, Mattia Fabio Molle, Emanuele Cozzani, Aurora Parodi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9091

  2627

  PDF: 633

  HTML: 6

• Adalimumab-induced facial erysipelas and its successful resolution with azithromycin in a 19-year-old female

  Caterina Mariarosaria Giorgio, Anna Balato, Gaetano Licata, Giuseppe Argenziano, Vittorio Tancredi, Eugenia Veronica Di Brizzi

  21-02-2025

  https://doi.org/10.4081/dr.2025.10278

  458

  PDF: 295

  HTML: 11
• 

  Herpes vegetans, an atypical herpes lesion in HIV patient: A case report

  Sondang P. Sirait, Wresti Indriatmi

  14-03-2022

  https://doi.org/10.4081/dr.2022.9180

  2636

  PDF: 845

  HTML: 16

• Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective

  Alba Guglielmo, Maria Ludovica Deotto , Luigi Naldi , Giuseppe Stinco, Alessandro Pileri, Bianca Maria Piraccini, Anna Belloni Fortina, Andrea Sechi

  13-09-2023

  https://doi.org/10.4081/dr.2023.9839

  2692

  PDF: 982

  HTML: 31

• A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks

  Luciano Ibba, Luigi Gargiulo, Giulia Pavia, Alessandra Narcisi, Antonio Costanzo, Mario Valenti

  06-06-2023

  https://doi.org/10.4081/dr.2023.9722

  798

  PDF: 460

  HTML: 17
• 

  Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data

  Aikaterini Kyriakou, Anastasia Trigoni, Nikiforos Galanis, Dimitrios Sotiriadis, Aikaterini Patsatsi

  01-10-2018

  https://doi.org/10.4081/dr.2018.7859

  1986

  PDF: 1058

  HTML: 64
• 

  Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema

  Nicoletta Bernardini, Nevena Skroza, Giovanni Rossi, Alessandra Mambrin, Ersilia Tolino, Federica Marraffa, Martina Caviglia, Antonio Di Guardo, Salvatore Volpe, Ilaria Proietti, Concetta Potenza

  21-11-2022

  https://doi.org/10.4081/dr.2022.9447

  1307

  PDF: 405

  HTML: 45

• Pityriasis following COVID-19 vaccinations: a systematic review

  Laura Duzett, Guadalupe Mercado, Vasiliki Tasouli-Drakou, Alicia Kane, Alison Tam

  09-08-2023

  https://doi.org/10.4081/dr.2023.9742

  1336

  PDF: 738

  Supplementary Material: 137

  HTML: 79
• 

  Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature

  Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen

  11-10-2017

  https://doi.org/10.4081/dr.2017.7079

  1382

  PDF: 663

  HTML: 142